Q12023 Bio-Rad Laboratories Inc Earnings Call
Good afternoon. Thank you for attending to bio Rad first quarter 2023 earnings Conference call. My name is Matt and I will be your moderator for today's call all lines will be muted during the presentation portion of the call up an opportunity for questions and answers at the end.
Do you feel like the ask a question. Please press star one on your telephone keypad.
I'd now like to pass the conference over to our host Ed shown head of Investor Relations.
Ed. Please go ahead.
Thanks, Matt.
Good afternoon, everyone and thank you for joining US today, we will review the first quarter 2023 financial results and provide an update on key business trends for bio Rad.
With me on the call today are Norman Schwartz, our Chief Executive Officer, Ilan, Daskal Executive Vice President Chief Financial Officer, Andy last Executive Vice President and Chief Operating Officer, Simon May President of the life Science group and our REIT President of our clinical diagnostics group.
Before we begin our review of light.
I would like to caution everyone that we will be making forward looking statements about managements goals plans and expectations, our future financial performance and other matters. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties actual results may differ materially from these plans and goals.
And expectations.
You should not place undue reliance on these forward looking statements and I encourage you to review our filings with the SEC, where we discuss in detail the risk factors in our business. The company does not intend to update any forward looking statements made during the call today.
Finally, our remarks today will include references to non-GAAP financials, including net income.
And diluted earnings per share, which are financial measures that are not defined under generally accepted accounting principles investors should review. The reconciliation of these non-GAAP measures to the comparable GAAP results contained in our earnings release.
I will now turn.
The call over to a lot of that goal.
Executive Vice President and CFO .
Thank you Ed good afternoon, and thank you all for joining us.
Before I begin the detailed first quarter discussion I would like to ask Andy last our chief operating officer to provide an update on <unk> global operations Andy.
Thank you Lasse.
Good afternoon everybody.
Now the first quarter of 2023 was characterized by solid growth for our core business.
Coupled with a significant reduction of Covid related sales.
However, we also experienced a number of market and operational challenges, which overall resulted in a lower than expected performance for the quarter.
While demand generally across the portfolio was in line with our expectations.
So there was some softness in smaller biopharma companies.
Where we have seen historically strong demand for our life science products.
This correlates with funding constraints for the industry is starting to experience in the first quarter.
We also saw a lower quarter for all of our process chromatography products, primarily reflecting the softness due to the timing of orders.
In addition, we saw a further tightening of sanctions, which impacted our business in Russia with a negative impact on sales in the quarter.
And we now expect lower overall performance for the year in Russia, especially in our life science business.
On the operational front, we did not make the expected pace of progress, but not within our supply chain to address our order backlog and as a result, backorder reduction was modest.
Of the estimated $30 million, we expect to recognize from elevated 2022 back orders.
We achieved a reduction of approximately $5 million in the first quarter and.
We expect a similar amount for the remaining three quarters of the year.
This was in part driven by a slower than expected ramp up of production in our new Singapore facility.
This also contributed to a higher than typical finished goods inventory as we made the transfer.
Our backlog was also impacted by the shift in sales mix and by the placement of more clinical systems unexpected at low margins.
We also experienced cost inflation that was higher than our net price realization in the quarter.
All of these factors affected gross margins for the quarter.
We saw an increase in demand for our clinical business globally as the impact of Covid to finally receded and.
In addition demand for our newly launched DD PCR platform <unk> 600.
Continued a strong trend line from Q4, 2022, and our pipeline is robust and growing and we are seeing strong uptake in biopharma translational research and oncology.
Yeah.
The market launch of <unk> continuum are more affordable digital PCR products remains on track for year end and.
And we launched a few weeks ago, the new PTC Kimco product line, our next generation of PCR thermal cyclists.
Yeah.
We completed development and early access of our DD PCR micro satellite instability kits and we will be launching later this quarter.
This assay kit includes an automated analysis package and enable clinical research says to assess microsatellite instability.
Status across multiple cancers, and as part of our expanding oncology assay menu for droplet digital Pcr.
Overall, we were pleased with the over 6% currency neutral core sales growth for the first quarter. Despite the year over year decline in Cogan sales.
In particular, we are very encouraged by the high demand in our clinical diagnostics business as we expand our installed base, providing a solid foundation for increased reagent pull through and continued long term growth.
Looking forward to the remainder of this year, we expect strong demand for our clinical systems to continue and we also expect continued double digit demand for our life science business.
We expect to see strong growth for our process chromatography business. All of this is now forecasted to be slightly lower than initial estimations.
On the supply chain front, we are expecting to clear our extended life science backlog by the end of the second quarter and our clinical backlog by the end of the year.
In addition, as we progress through the remainder of the year, we expect production to continue to ramp up in Singapore as.
As well as expansion of capacity for the <unk> 600, DD PCR system has initial demand in Q1 exceeded our ability to fulfill.
And with that I'll say, thank you and pass you back to the lab.
Thank you Andy now I would like to review the results of the first quarter.
Net sales for the first quarter of 2023 were $676 $8 million, which is a three 3% decline on a reported basis versus $701 million in Q1 of 2022.
On a currency neutral basis, the year over year revenue decline was 0.3%.
The first quarter of year over year revenue decline was mainly the result of significantly lower COVID-19 related sales of approximately $2 $6 million.
Versus $45 million in the first quarter of last year.
Core revenue, which excludes COVID-19 related sales increased six 1% year over year on a currency neutral basis.
As Andy alluded to earlier, our Q1 results were impacted by increased sanctions in Russia increased early stage biotech companies pressures and continuing certain supply chain challenges, including those associated with our manufacturing lines transfer and ramp up in Asia.
The production transition contributed to a continued elevated order backlog mainly within the diagnostics group.
In addition, we continue to ramp capacity to accommodate the growing demand for the new <unk> 600, DD Pcr system.
On a geographic basis, we experienced currency neutral year over year core revenue growth in the Americas and Europe , while core revenue modestly declined in Asia, primarily due to a tough compare for the process chromatography franchise related to a very large customer order in the year ago period.
Sales of the life Science group in the first quarter of 2023 were $323 6 million compared to $347 2 million in Q1 of 2022, which is a decrease of six 8% on a reported basis and a decline.
Three 6% on a currency neutral basis.
The underlying life science year over year currency neutral core revenue growth was nine 6% and was primarily driven by our Q PCR products Western blotting and droplet digital Pcr.
This growth was lower than we projected as a result of increased sanctions effective sales of certain products to Russia as well as growing revenue headwind from Biopharma companies due to the funding environment for early stage biotech companies.
As I mentioned earlier, we continue to ramp capacity to accommodate the growing demand for the new <unk> 600, DD Pcr system.
Process chromatography revenue, which can fluctuate on a quarterly basis posted a mid single digit year over year decline due to a tough compare as well as some softness in the bio processing market.
With that being said, we will expect we still expect double digit growth for 2023, despite a lower revenue projection relative to our prior forecast.
Excluding process chromatography sales the underlying life science business declined three 3% on a currency neutral basis versus Q1 of 2022.
<unk> was a result of lower Covid related sales.
The life Science group revenue, excluding process chromatography, and Covid related sales grew 13, 6% on a currency neutral basis.
On a geographic basis life science experienced currency neutral year over year core revenue growth in the Americas and Europe , while Q1 core revenue posted a decline in Asia due to the previously mentioned tough compare for process chromatography.
Yeah.
Sales of clinical diagnostics group in the first quarter were $362 1 million compared to $351 8 million in Q1 of 2022 or largely flat on a reported basis and two 8% increase on a currency neutral basis.
Core clinical diagnostics year over year revenue, which excludes COVID-19 related sales increased three 1% on a currency neutral basis.
Growth of the clinical diagnostics group was primarily driven by a robust demand for diagnostics instruments.
Primarily within blood typing and diabetes, which was not entirely fulfilled due to our manufacturing constraints.
We continue to see strong rebound in placements of instruments in China, which should contribute to reagent pull through volumes in the coming quarters.
On a geographic basis currency neutral year over year core revenue for the diagnostics group.
Hosted a double digit growth in Asia and were largely flat in the Americas and Europe versus the year ago period.
The reported gross margin for the first quarter of 2023 was 53, 5% on a GAAP basis and compares to 57, 5% in Q1 of 2022.
The year over year gross margin decline was mainly due to lower COVID-19 related sales unfavorable product mix and higher cost raw materials.
The gross margin. This year was further impacted by higher than anticipated percentage of instrument sales versus reagents as well as from the lower than forecasted revenue in the life Science group.
In addition, we were not able to fully recover the higher inflationary costs. This year as the increases in certain raw materials and elevated logistics costs were not fully recovered in selling prices.
Amortization related to prior acquisitions recorded in cost of goods sold was $4 3 million compared to $4 $5 million in Q1 of 2022.
SG&A expenses for Q1 of 2023 were $225 6 million.
Or 33, 3% of sales.
Compared to $196 7 million or 28, 1% in Q1 of 2022.
The increase in SG&A expenses was driven by higher employee related expenses and restructuring charge and higher discretionary spend.
Total amortization expense related to acquisitions recorded in SG&A for the quarter was $1 7 million versus $1 8 million in Q1 of 2022.
Research and development expense in the first quarter was $75 million or 11, 1% of sales compared to $59 5 million or eight 5% of sales in Q1 of 2022.
The year over year increase was due to increased employee related expenses.
Following the curiosity acquisition in the third quarter of 2022.
Higher project related spend.
And the restructuring costs.
Q1, operating income was $61 9 million or.
Or nine 1% of sales compared to $146 4 million or.
Or 29% of sales in Q1 of 2022.
Looking below the operating line the change in fair market value of equity Securities Holdings, which are substantially related to BIOLASE ownership of Sartorius AG shares negatively impacted our reported results by $17 5 million.
During the quarter interest and other income resulted in net other income of $44 million compared to net other income of $37 million last year.
Q1 of 2023 included a $34 8 million dividend from Sartorius.
It says $31 $6 million dividend in the first quarter of 2022.
The effective tax rate for the first quarter of 2023 was 18, 7% compared to 22, 9% for the same period in 2022.
The effective tax rate reported in Q1 of 2023 was primarily affected by geographical mix of earnings.
The effective tax rate reported in Q1 of 2022 was primarily affected by an unrealized loss in equity securities.
Reported net income for the first quarter was $69 million or $2 32 diluted earnings per share compared to a loss of $3 billion and $367 million or $112 50.
Loss per share in Q1 of 2022.
This change from last year is largely related to changes in the valuation of the Sartorius holdings.
Moving on to the non-GAAP results.
Looking at our results on a non-GAAP basis, we have excluded certain atypical and unique items that impacted both the gross and operating margins as well as other income.
These items are detailed in the reconciliation table in the press release.
Looking at the non-GAAP results for the first quarter in cost of goods sold we have excluded $4 3 million of amortization of purchased intangibles and small restructuring expense.
These exclusions moved the gross margin from 53, 5% for the first quarter of 2023 to our non-GAAP gross margin of 54, 2% versus 58, 2% in Q1 of 2022.
non-GAAP SG&A in the first quarter of 2023 was 31, 3% versus 27, 2% in Q1 of 2022.
In SG&A on a non-GAAP basis, we have excluded amortization of purchased intangibles of $1 $7 million.
In in vitro diagnostic registration fee in Europe for previously approved products of $1 9 million.
Acquisition related cost of $800000.
$9 million of restructuring related expenses.
non-GAAP R&D expense in the first quarter of 2023 was 10, 4% versus eight 5% in Q1 of 2022.
In R&D on a non-GAAP basis, we have excluded $4 2 million of restructuring expenses.
The cumulative sum of these non-GAAP adjustments result in moving the quarterly operating margin from nine 1% on a GAAP basis to 12, 4% on a non-GAAP basis.
non-GAAP operating margin compares to a non-GAAP operating margin of 22, 4% in Q1 of 2022.
We have also excluded certain items below the operating line, which are the decreasing value of the sartorius equity securities and loan receivable holdings of $17 5 million.
And about a $1 million loss associated with venture investments.
The non-GAAP effective tax rate for the first quarter of 2023 was 29% compared to 19, 6% for the same period in 2022.
The higher rate in 2023 was driven by geographical mix of earnings and lower compensation related deductions.
And finally non-GAAP net income for the first quarter of 2023 was $99 4 million or $3 34 diluted earnings per share compared to $161 5 million or diluted earnings per share of $5.
$5 and <unk> <unk> in Q1 of 2022.
Moving onto the balance sheet.
Total cash and short term investments at the end of Q1.
Was $1 billion and $857 million compared.
Compared to $1 billion and $796 million at the end of 2022.
The change in cash and short term investments from the fourth quarter of 2022 was primarily due to the change in working capital.
Inventory at the end of Q1 reached $752 9 million from $719 3 million in the prior quarter.
The higher inventory level was driven mainly by rebuilding of finished goods safety stock for certain instruments.
In addition, we are rebalancing inventory levels.
We complete the transition of some of our manufacturing.
We did not purchase any shares of our stock during the first quarter, but as we have done in recent years coming out of blackout periods. We will continue to be opportunistic with share buybacks, particularly when we believe the reasons.
Significant dislocation in the valuation of our stock.
To that end, we have over $200 million available to deploy under the current board authorized program.
For the first quarter of 2023 net cash generated from operating activities was $98 1 million, which compares to $55 million in Q1 of 2022.
This increase mainly reflects changes in working capital.
The adjusted EBITDA for the first quarter of 2023 was $148 5 million or.
Or 21, 9% of sales and excluding the sartorius dividend was 16, 8%.
The adjusted EBITDA in Q1 of 2022 was $215 4 million or 38% of sales and excluding the sartorius dividend was 26, 3%.
Net capital expenditures for the first quarter of 2023 were $35 7 million.
And depreciation and amortization for the first quarter was $35 6 million.
Moving on to the non-GAAP guidance.
Taking into account the macro economic factors.
Well as our continued operational transformation initiatives, we are revising our 2023 financial outlook as follows.
We are now guiding currency neutral revenue growth in 2023 to be about four 5% versus 6% to 7% previously.
For the full year, we estimate currency neutral revenue growth, excluding COVID-19 related sales to be about eight 5% versus 10% to 11% in our prior guidance.
We expect the first half of 2023 core growth to be between six 5% and 7% over the first half of 2022 and.
And about 10% core growth in the second half of the year over the second half of 2022.
The life Science group year over year currency neutral revenue growth is expected to be about 3% versus 8% to 9% and excluding COVID-19 related sales. The life Science group growth is projected to be about 11% versus 16% to 18%.
Our prior guidance.
For the first half of 2023, we expect for the life Science group about nine 5% core growth over the first half of 2022.
And about 12, 5% core growth for the second half of the year over the second half of 2022.
For the diagnostics group, we estimate currency neutral revenue growth of about 6%.
5% previously as we are seeing improved demand dynamics in 2023.
Excluding COVID-19 related sales the diagnostics group growth is projected between six and six 5% versus five to five 5% in our prior guidance.
For the first half of 2023, we expect for the diagnostics group about four 5% core growth over the first half of 2022 and about 8% core growth for the second half of the year over the second half of 2022.
Full year non-GAAP gross margin is now projected to gradually improve throughout 2023 and be between 55 and 55, 5% for the full year.
For the first half of the year, we now anticipate gross margin to be between 54, 5% and 55%.
And for the second half of the year to be between $55 five and 66%.
We now project full year non-GAAP operating margin of approximately 17, 5% versus 19, 5% in our prior guidance as we plan to focus on expense management for the remainder of the year.
For the first half of the year, we expect operating margin to be about 14% and reaching 21% for the second half of 2023.
And full year adjusted EBITDA margin is expected to be about 23% versus 25% in our prior guidance.
For the first half of the year, we expect adjusted EBITDA margin to be about 21% and in the second half of the year to be about 25%.
Yeah.
We are also revising our targeted 2021% to 2025 currency neutral compounded annual revenue growth rate to be 8% versus our previous target of eight 9%.
For the life Science business, we are now targeting about 12, 4% between 2021 and 2025 versus our prior expectations of approximately 13, 9%.
For clinical diagnostics business, we now expect four 4% versus four 6% previously.
Our gross margin in 2025 is targeted to be about 57% versus our previous target of 59%.
And our adjusted EBITDA for 2025 is targeted to be about 26% versus our previous target of 28%.
That concludes our prepared remarks, and we will now open the line to take your questions.
Operator.
Absolutely.
I'd like to ask a question. Please press star followed by one on your telephone keypad. If for any reason you would like to remove that question. Please press star followed by two.
Again to ask a question press star one.
As a reminder, if you are using a speaker phone. Please remember to pick up your handset before asking a question, we'll pause briefly as questions you registered.
The first question is from the line of Brian <unk> with Jefferies. Your line is now open.
Hey, good afternoon.
Thanks for taking the questions.
Okay I appreciate all the detail.
Can you just walk through there like a pack I'd just start with a 23 guidance reset on the top line can you help us bridge the components and the puts and takes between Russia weakness early stage Biopharma lower process media demand.
And secondarily, what gives you the confidence in terms of the second half acceleration.
On the top line should start there.
Hi, Brian it's Andy actually so I, maybe maybe I'll just walk through.
Sure the answer to that and you did capture the big leave us in.
Once out of Russia, which has had a meaningful impact buyer.
Biopharma softness switch does.
We did have some impact, particularly in the kind of let's call it emerging biopharma companies.
Is that.
But financial.
Access to capital in Q1, which which flowed through to.
Brought demand broader kind of slowdown in demand for our life science.
Products.
The process CRO story is not so much an emerging biopharma story as much as you know.
I think we're finally now just seeing some of the effect.
Of the overall inventory rebalancing that has been going on in the industry and we have not been seeing that previously.
I'd say the last two points to two highlights on the revenue bridge would be.
Slower pace of Backorder reduction, which.
I think we're saying we're able to capture everything that we initially.
We estimated.
<unk>.
Related to our gene expression business, just generally softer demand for that.
Yes.
Being experienced this year against a very significant installed base that we had previously put out there over the last two or three years.
Okay.
Maybe.
In terms of the 25 targets I mean, just generally conceptually why update those now, especially given what seems to be all the operational.
Challenges, we faced in the quarter and macro variables.
Got it on the call.
<unk> two.
Can you share what the applied targets.
The in terms of revenue dollars and 25 and if my math is right would that suggest kind of 8% organic CAGR. The next three years.
To get there.
Yeah, Brandon Thanks for the question so.
First of all update.
Updating the 2025 based on our latest view and in light of the.
The changing environment that we are experiencing.
Obviously as.
As Andy mentioned, just now the entire kind of biotechnology sector underfunding.
That was one of the growth drivers that we called out during the Investor day, and we see headwind there. The overall inflationary kind of cost that we today believe is here to stay and I'm not sure that TEP is transitory and that was not taken into account.
When we presented during the Investor day.
So we are left with layering on.
What does that mean for the next.
Two to three years.
And we do believe the neon comerica.
An update to the 2025 target model in order to set the expectation with that said.
It doesn't change our thinking in terms of the overall transformation that we are working on and everything that we still plan to achieve and all the kind of new instruments that are in the pipeline and the development in.
And so so that doesn't change our thinking it's more kind of I would argue macro driven.
And we have to kind of communicate accordingly.
In terms of the growth.
Yes, I mean.
So.
Your math is correct is about on a core basis, its about 8% and.
And that's the update it if you think about the currency neutral basis.
Three for three.
$3 4 billion for 2025 on a currency neutral basis.
Got it last one for Simon maybe your closest competitor.
Digital PCR earlier, Dave talked about.
Our market.
CAGR next three years in the 30% to 40% range.
That's consistent with your view.
How you would assess the market and if you view.
The opportunity in the growth outlook.
Definitely.
Okay.
No that's definitely emerging competition in digital PCR without a doubt.
We all observe that very closely and we take it very seriously and as we've said before I think it really is also helping to significantly expand.
The market opportunity in <unk>.
We see that.
Commentary in the disclosures from our competitors and we kind of overlay that with the growth trajectory that we see in our own business. We think it's pretty consistent overall than we think keeps playing out the way that we thought it would.
And then when we think about our overall position today with thoughts about how the demand for the Kuwait 600 platform and customer acceptance is really fantastic.
So we're feeling good about that and in the Biopharma segment.
Notwithstanding some of the market softness that we're seeing at the present time, we've got a very strong position that we think the market is ultimately go.
Very long legs, and I think we got quite a nice moats around our business, we called a really formidable pull.
Folio of high performance <unk> and.
We know in this segment that performance really really matters and our <unk> platform.
Is really best in class in terms of throughput and automation and then as was mentioned earlier, we've already got the culex continuum platform not seen developments in our consulting about programs running quite nicely.
So when we think about the overall dynamics here I don't think anything has fundamentally changed since we discussed this at Investor day.
I will hop back in the queue. Thanks.
Thank you Brendan.
Thank you for your question.
The next question is from the line of Patrick Donnelly with Citi. Your line is now open.
Okay.
Hey, guys. Thanks for taking the question.
Maybe a similar question on the process chrome side. It sounds like you saw a pretty good slowdown in the quarter.
Andy I think you called out timing has an impact, but obviously the guidance coming down pretty significantly for the year. How much do you think timing versus change in demand. What are you seeing in the market and what's the ability to execute in the backdrop of.
Again, if the demand is holding up is it just a execution issue, maybe just kind of give us a little more color there.
Yes.
Timing is always a challenge for that business.
And I'm sure you guys, you know that well but.
And then in Q1 in particular is a tough compare to try try year for us so.
That really wasn't a great surprise from that point of view.
Looking forward.
I think we are just starting to experience some of the kind of.
And we're calling it.
Inventory rebalancing and just a more prudent of our conservative approach from from the end market.
As we as we go forward and we feel it's prudent to reflect that and the way we're thinking about our guidance this year.
Underlying all of that is.
Extremely extremely solid and consistent demand for the process crime business.
The new products, we have introduced have been exceedingly well.
<unk> received and we're starting to see uptake in traction on bars.
Go forward thesis on process.
We're finally seeing.
Some of the effects that I think others have been calling out for a while where we're finally seeing a little bit of that.
Floods rates while business now.
Okay, that's helpful and along maybe on the on.
On the margin side, I think you've called out some maybe more.
Aggressive expense management.
Yes, as you think about that.
First half and second half ramp in the margins can you just talk about what levers you guys are pulling.
The visibility into hitting those numbers, we've got a pretty pretty good step up from first half to the second.
Yes. Thank you Patrick I appreciate the question so.
We have several initiatives that are in flight and it's part of our kind of plan already.
We anticipate that we will be able to realize eight in the second half.
And it will roll over also into next year.
And these are obviously multiple initiatives that.
We are pretty confident that we will be able to achieve its part of the guidance obviously 2018.
Obviously.
The goal there is to mitigate the softness that we are.
Guided for on the top line as well as some aspect of the of the gross margin.
And I think that we have a very good plan to achieve it and it's mainly focused on the second half of this year.
Okay.
And then maybe on the long term guide you now life Science came down I think 150 bps. When you think about that change to the gross billed in terms of the algorithm you guys have.
The scene there.
I guess what segments were the biggest step downs I mean, the digital PCR changed at all with the process Chrome. If you can just help us think about.
What softened and that algorithm and I think when you guys gave the guy who didn't get a ton of building blocks. So just trying to figure out.
What areas, maybe it was all of them, but just just if you could help us out there that'd be helpful.
Yeah, Patrick Let me, let me take a shot at this question I think what we've what we've determined is.
Is that.
The Biopharma softness is contributing to life science Scruggs at a slower pace.
The simplest way to think about it.
And with.
With the with the kind of shakeout, that's gone on a little bit and emerging smaller biotech companies, where we've had meaningful business and very strong growth.
And just if that effect flowing through over the next couple of years.
And I wouldn't think of it as anything more than that at this point in time.
Just to reiterate that the fundamental pillars in.
And the life science business on process chromatography, and droplet digital PCR and then related products.
Very solid, so where where I think prudently.
Putting forward that we see.
Slower growth as a result, I think as well, Russia wasn't part of the initial calculus and now it is it's not a massive impact.
Dan and that flows through to the projection as well.
Understood. Thank you guys.
Thank you Patrick.
Thank you for your question.
The next question is from the line of Dan Leonard with Credit Suisse. Your line is now open.
Thank you I think Brendan asked this question, but I'm not sure I caught the answer.
Is it revised guidance still assumes a meaningful sales acceleration in two H.
Fourth quarter comp is tough macro is not getting better. So what are you looking at to support that second half ramp.
Okay.
Yes.
So so we do see a slightly lower growth projections from from our life Science business, which I think we just reflected in the commentary.
Which is.
Partially offset by an improved performance in the clinical business in the second half.
We're seeing actually fairly robust demand for our clinical systems.
That we expect to continue its obviously you got a little bit of a mix shift playing out there.
Across the three business groups.
Which will further help to support the second half performance.
A small mix impact on margin.
Which were also reflecting because of the differential between the two business groups yes.
Add to that also that from there obviously it flows throughout the P&L the gross margin.
Expect it to improve.
As the year progresses.
As well as we have.
A list of initiatives.
Our in flight and some that are scheduled.
To start that.
Will benefit the second half.
I've got one final factor.
Which is.
The.
Burn down of backlog in the second half an hour and so.
We have much better line of sight to that.
Anything of that in the <unk>.
Second half and that will also contribute to the second half growth.
<unk> and <unk> 600 on the life science side.
It's a very robust pipeline, yes, so in the Q 600, yes, exactly Andy I mean.
It's about the manufacturing kind of volume that we plan to have a much higher volume in the second half than in the first half.
Obviously, a nice contribution not only about the top line, but it's above average.
Generally flow through.
Okay.
And then my follow up question, Andy you commented on softer demand for gene expression again significant installed base.
Why isn't that a multiyear problem.
Well I think I think as we move forward. It is an element I think it's a good a good point, you're making there and its an element that is factored into the life science.
Forward looking view.
On the 25 trajectory right.
It is it is a factor that it's hard to really quantify in the market. After you placed all these instruments over the last two plus years three years.
So it's a good call out and it's a fair point, but it is it is considered in our.
25, <unk> guides for life Science.
Okay. Thank you.
Thank you Dan.
Thank you for your question.
The next question is from the line of Jack Meehan with Nephron Research. Your line is now open.
Thank you good afternoon.
First question is on the Russian sanctions can you just quantify for us the impact that's now embedded in your forecast then when does it start.
I guess one more annualized.
Yes.
Thank you Jeff I appreciate the question.
Historically, we called out that Russia.
It was between one and 2% of revenue on an annual basis, obviously, the sanctions kept accumulating and when we started the year, we still have a nice pipeline.
<unk>.
I would say that about a third of our projects in more than a third of the projection for this year.
Was impacted by incremental sanctions that we.
We had to revise eight this quarter these are not the.
Prior to sanction these are incremental sanctions that prevents us from.
Shipping.
More than a third of our projected oil prior projection for this year.
Mhm.
Got it and then in the diagnostics business. So it sounded like regionally you did well in Asia.
I was just curious if you could comment on what Youre seeing here in the U S and in Europe .
I think I heard largely flat we've been hearing about better volumes from a lot of the services providers.
<unk>.
Just how is that playing through in your U S and Europe business.
Yes, I believe we have Dara <unk> dialed in remotely. So there are not sure what are you able to hear the question.
Yeah. Thank you. Thank you. Thanks for the question Dara airline can you hear me Okay. Yes.
Yes. Thank you.
Great.
So demand is strong in all regions.
Elevated.
Asia Pacific as a consequence, China opening back up.
With that the Covid restrictions lifted in Q1.
The actual sales, where we're sort of bias towards Asia Pacific in Q1, so the revenue with with bias, there, but but demand and backlog.
Similarly.
Sort of higher than than.
That historically.
In America.
We as we burn down that backlog, you know, replacing that placing instruments globally.
<unk> increased our installed base.
Great.
One final one for Norman.
We're in this.
The macro environment, which is evolving a little bit your business. It should be I think more defensive when it's all said and done just was curious.
How kind of the evolving landscape might change your philosophy, if at all when it comes to M&A and.
What youre seeing in the tunnel. Thank you.
Yes, so the funnel remains about the same.
Sure.
Obviously when when.
When you think about kind of valuations coming in it.
It's a little stickier on the way down.
So that's a dynamic that debt.
That I think we are aware of.
But again, we've got a couple of things in the Hopper.
And we continue to see it as a.
Yes.
A viable option for for cash deployment.
As we go forward to add to the business.
Thank you for your question.
The next question is a follow up from Brandon <unk>. Your line is now open.
Okay. Thanks.
Just to push back on your answer to Patrick's question I think.
The biopharma.
Exposure that you have only 15% youre talking about a sliver of that overall market first of all I'll make sure I understand that right and then what's embedded in your outlook for that earlier stage buyer.
Biotech customer base could you quantify it.
Sizing, but also what youre expecting in terms of growth from that market.
Yes.
Brendan.
I don't think we've quantified.
Our segmented.
Our sales within the Biopharma segment overall.
We have done, particularly well in emerging biotech, especially because of cell and gene therapy based therapeutic development, there and fitness companies.
But the.
So that's more of a broader life science.
Product impact the.
The process Chrome is obviously for the much more in a minute.
Mid and large sized biopharma companies.
And.
There I think we're just we're just literally subject to to the macros that have been going on across the industry, which we had not seen before and it's.
Started to show up a bit for us this year. So we've moderated our growth expectations. This year, although they are still good healthy double digit growth for the bio processing side of the business.
I'll just maybe add.
A third of our life Science revenue is contributed from Biopharma way pretty overweight.
Small and emerging biotech companies, whether you're talking about process chromatography and wheatstone.
It's about as previously how are resonating so rarely play in these emerging biologic therapeutics.
Also in our life science portfolio generally.
We see that Halo effects.
Emerging bought <unk> more so than big pharma, which tends to be locked.
It really large contracts.
Okay.
Last one for Alon.
Make sure.
Definitions, we understand correctly you are 25 EBITDA margin target that includes the sartorius dividend just want to make sure.
And how much.
Executives and contemplate.
$34 million this year or.
Good luck.
The dividend last year at the analyst day, which is much different.
Yes, so we try to compare is kind of apples to apples.
And back in the Investor Day, we said that it included about $19 million of dividend.
And in that.
And that's what we assume now to be consistent.
Got it thank you.
Thank you Brendan Thank you for your question.
There are no additional questions waiting at this time, so I'll pass the conference back to the management team for any closing remarks.
Thank you for joining today's call we will be at the RBC capital markets Global Healthcare Conference in New York later this month.
And also in New York, The Jefferies Healthcare conference in June .
As always we appreciate your interest and we look forward to connecting soon.
Thanks.
That concludes the conference call. Thank you for your participation you may now disconnect your lines.
Now disconnect your lines.